Table 3.
Summary of results from quantitative surveys.
| Center | Percentage of REMG participants in cancer clinical trials | REMG populations engaged in cancer clinical trials | Availability of metric scorecard | Where OMH REMG data is captured | How and by whom OMH REMG data is captured | Format of REMG data capture |
|---|---|---|---|---|---|---|
| FCCC | 10–20% | African Americans, Hispanic Americans, Asian Americans | Yes, use NCI grant Criteria* for REMGs | Captured in clinical trial database by research staff and non-research staff throughout continuum | Patient reported (directly) | Written and web-based |
| UTSW | 30–40% (40–50% in population science research) | African Americans, Hispanic Americans | Yes, use NCI grant Criteria* for REMGs | Captured in clinical trial database by research staff and non-research staff throughout continuum | Reported by research staff, informed by direct patient query | Written and web-based |
| HFCI | 30–40% | African Americans | Yes (extensive metrics provided) | Captured in clinical trial database by research staff and non-research staff throughout continuum | Reported by research staff, informed by direct patient query | Written and web-based |
| MUSC | 20–30% (27% in interventional trials & 32% in non-treatment trials) | African Americans, Hispanic Americans | Yes, extensive metrics provided and NCI Grant Criteria* for REMGs | Captured in clinical trial database by research staff and non-research staff throughout continuum | Patient reported (directly) | Written |
| JVCI | 10–20% | American Indians, Alaskan Natives (primarily from Lakota Country) | Yes (extensive metrics provided) | Captured in clinical trial database | Patient reported (directly) | Written and web-based |
| MDACC | 10–20% | African Americans, Hispanic Americans, Asian Americans | Yes, extensive metrics provided and NCI Grant Criteria* for REMGs | Captured in clinical trial database | Patient reported (directly) | Web-based |
| UCDCCC | 30–40% (30–40% Asian Am. participants in non-interventional research) | Asian Americans | Yes, use NCI grant Criteria* for REMGs | Degree/extent of capture in clinical trial database unknown | Reported by research staff, based on visual observation | Written |
| WCI-EMORY | 20–30% | African Americans, Hispanic Americans | Yes (extensive metrics provided) and NCI grant Criteria* for REMGs | Captured in clinical trial database by research staff and partners throughout continuum | Varies by trial | Written and web-based |
FCCC, Fox Chase Cancer Center/Temple Health (Philadelphia, PA); UTSW, Harold C. Simmons Comprehensive Cancer Center/UT Southwestern Medical Center (Dallas, TX); HFCI, Henry Ford Cancer Institute (Detroit, MI); MUSC, Hollings Cancer Center/MUSC (Charleston, SC); JVCI, John T. Vucurevich Cancer Institute/Rapid City Regional Hospital (Rapid City, SD); MDACC, MD Anderson Cancer Center/UT (Houston, TX); UCDCCC, UC Davis Comprehensive Cancer Center (Sacramento, CA); WCI-EMORY, Winship Cancer Institute/Emory (Atlanta, GA); REMGs, racial and ethnic minority groups; OMH, Office of Minority Health. *NCI Comprehensive Cancer Center Research Strategy Expectations for Catchment areas. Available at: https://cancercenters.cancer.gov/documents/CCSGFAQs508C.pdf (accessed May 01, 2019).